Primary Focal and Segmental Glomerulosclerosis and Soluble Factor Urokinase-type Plasminogen Activator Receptor

Overview

Journal World J Nephrol

Publisher Baishideng Publishing Group

Specialty Nephrology

Date 2013 Nov 21

PMID 24255893

Citations 14

Authors

Hernan Trimarchi

Affiliations

Soon will be listed here.

Abstract

Primary focal and segmental glomerulosclerosis (FSGS) may be due to genetic or acquired etiologies and is a common cause of nephrotic syndrome with high morbidity that often leads to end-stage renal failure. The different available therapeutic approaches are unsuccessful, in part due to partially deciphered heterogeneous and complex pathophysiological mechanisms. Moreover, the term FSGS, even in its primary form, comprises a histological description shared by a number of different causes with completely different molecular pathways of disease. This review focuses on the latest developments regarding the pathophysiology of primary acquired FSGS caused by soluble factor urokinase type plasminogen activator receptor, a circulating permeability factor involved in proteinuria and edema formation, and describes recent advances with potential success in therapy.

Citing Articles

Roles of Immune Cells in Hereditary Angioedema.

Ferrara A, Cristinziano L, Petraroli A, Bova M, Gigliotti M, Marcella S Clin Rev Allergy Immunol. 2021; 60(3):369-382.

PMID: 34050913 PMC: 8272703. DOI: 10.1007/s12016-021-08842-9.

Mechanisms of Podocyte Detachment, Podocyturia, and Risk of Progression of Glomerulopathies.

Trimarchi H Kidney Dis (Basel). 2021; 6(5):324-329.

PMID: 33490112 PMC: 7745660. DOI: 10.1159/000507997.

Circulating Soluble Urokinase-Type Plasminogen Activator Receptor Levels Reflect Renal Function in Newly Diagnosed Patients with Multiple Myeloma Treated with Bortezomib-Based Induction.

Terpos E, Ntanasis-Stathopoulos I, Papassotiriou G, Kastritis E, Margeli A, Kanellias N J Clin Med. 2020; 9(10).

PMID: 33022958 PMC: 7600599. DOI: 10.3390/jcm9103201.

Focal Segmental Glomerulosclerosis and Scheduled Pretransplant Plasmapheresis: A Timely Diagnosis of Nail-Patella Syndrome Avoided More Futile Immunosuppression.

Trimarchi H Case Rep Nephrol. 2020; 2020:8879555.

PMID: 32774956 PMC: 7396003. DOI: 10.1155/2020/8879555.

New therapeutic perspectives for IgA nephropathy in children.

Cambier A, Gleeson P, Flament H, Stang M, Monteiro R Pediatr Nephrol. 2020; 36(3):497-506.

PMID: 32040630 DOI: 10.1007/s00467-020-04475-w.

References

Santin S, Bullich G, Tazon-Vega B, Garcia-Maset R, Gimenez I, Silva I . Clinical utility of genetic testing in children and adults with steroid-resistant nephrotic syndrome. Clin J Am Soc Nephrol. 2011; 6(5):1139-48. PMC: 3087781. DOI: 10.2215/CJN.05260610. View

Troyanov S, Wall C, Miller J, Scholey J, Cattran D . Focal and segmental glomerulosclerosis: definition and relevance of a partial remission. J Am Soc Nephrol. 2005; 16(4):1061-8. DOI: 10.1681/ASN.2004070593. View

Sidenius N, Sier C, Blasi F . Shedding and cleavage of the urokinase receptor (uPAR): identification and characterisation of uPAR fragments in vitro and in vivo. FEBS Lett. 2000; 475(1):52-6. DOI: 10.1016/s0014-5793(00)01624-0. View

Andersen R, Buhl K, Jensen B, Svenningsen P, Friis U, Jespersen B . Remission of nephrotic syndrome diminishes urinary plasmin content and abolishes activation of ENaC. Pediatr Nephrol. 2013; 28(8):1227-34. DOI: 10.1007/s00467-013-2439-2. View

Maas R, Deegens J, Wetzels J . Serum suPAR in patients with FSGS: trash or treasure?. Pediatr Nephrol. 2013; 28(7):1041-8. DOI: 10.1007/s00467-013-2452-5. View

Svenningsen P, Bistrup C, Friis U, Bertog M, Haerteis S, Krueger B . Plasmin in nephrotic urine activates the epithelial sodium channel. J Am Soc Nephrol. 2008; 20(2):299-310. PMC: 2637049. DOI: 10.1681/ASN.2008040364. View

Hoyer-Hansen G, Ploug M, Behrendt N, Ronne E, Dano K . Cell-surface acceleration of urokinase-catalyzed receptor cleavage. Eur J Biochem. 1997; 243(1-2):21-6. DOI: 10.1111/j.1432-1033.1997.0021a.x. View

Ponticelli C . Recurrence of focal segmental glomerular sclerosis (FSGS) after renal transplantation. Nephrol Dial Transplant. 2009; 25(1):25-31. DOI: 10.1093/ndt/gfp538. View

Salomon R, Gagnadoux M, Niaudet P . Intravenous cyclosporine therapy in recurrent nephrotic syndrome after renal transplantation in children. Transplantation. 2003; 75(6):810-4. DOI: 10.1097/01.TP.0000055215.20367.21. View

10.

Passero C, Mueller G, Rondon-Berrios H, Tofovic S, Hughey R, Kleyman T . Plasmin activates epithelial Na+ channels by cleaving the gamma subunit. J Biol Chem. 2008; 283(52):36586-91. PMC: 2605981. DOI: 10.1074/jbc.M805676200. View

11.

Guigonis V, Dallocchio A, Baudouin V, Dehennault M, Hachon-LE Camus C, Afanetti M . Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases. Pediatr Nephrol. 2008; 23(8):1269-79. DOI: 10.1007/s00467-008-0814-1. View

12.

Garin E, Diaz L, Mu W, Wasserfall C, Araya C, Segal M . Urinary CD80 excretion increases in idiopathic minimal-change disease. J Am Soc Nephrol. 2008; 20(2):260-6. PMC: 2637046. DOI: 10.1681/ASN.2007080836. View

13.

Moudgil A, Bagga A, Jordan S . Mycophenolate mofetil therapy in frequently relapsing steroid-dependent and steroid-resistant nephrotic syndrome of childhood: current status and future directions. Pediatr Nephrol. 2005; 20(10):1376-81. DOI: 10.1007/s00467-005-1964-z. View

14.

Shankland S, Pollak M . A suPAR circulating factor causes kidney disease. Nat Med. 2011; 17(8):926-7. DOI: 10.1038/nm.2443. View

15.

Florquin S, van den Berg J, Olszyna D, Claessen N, Opal S, Weening J . Release of urokinase plasminogen activator receptor during urosepsis and endotoxemia. Kidney Int. 2001; 59(6):2054-61. DOI: 10.1046/j.1523-1755.2001.00719.x. View

16.

Sier C, Sidenius N, Mariani A, Aletti G, Agape V, Ferrari A . Presence of urokinase-type plasminogen activator receptor in urine of cancer patients and its possible clinical relevance. Lab Invest. 1999; 79(6):717-22. View

17.

Zhang B, Xie S, Shi W, Yang Y . Amiloride off-target effect inhibits podocyte urokinase receptor expression and reduces proteinuria. Nephrol Dial Transplant. 2011; 27(5):1746-55. DOI: 10.1093/ndt/gfr612. View

18.

Keith D . Therapeutic apheresis rescue mission: recurrent focal segmental glomerulosclerosis in renal allografts. Semin Dial. 2011; 25(2):190-2. DOI: 10.1111/j.1525-139X.2011.01031.x. View

19.

Ostergaard C, Benfield T, Lundgren J, Eugen-Olsen J . Soluble urokinase receptor is elevated in cerebrospinal fluid from patients with purulent meningitis and is associated with fatal outcome. Scand J Infect Dis. 2004; 36(1):14-9. DOI: 10.1080/00365540310017366. View

20.

McCarthy E, Sharma M, Savin V . Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis. Clin J Am Soc Nephrol. 2010; 5(11):2115-21. DOI: 10.2215/CJN.03800609. View